IL15 synergizes with radiotherapy to reprogram the tumor immune contexture through a dendritic cell connection

Abstract

IL15 is a key cytokine for the activation and survival of anti-tumor effectors CD8(+) T and NK cells. Recently published preclinical studies demonstrate that the therapeutic activity of IL15 requires conventional dendritic cells type 1 (cDC1). Radiotherapy cooperates with IL15 by enhancing cDC1 tumor infiltration via interferon type 1 activation.